JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
JMP Securities reiterated a Market Outperform rating on Sprinklr Inc (NYSE:CXM), with a steady price target of $17.00. The firm's analysts highlighted the company's current performance, which includes ...
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
In a report released today, David Turkaly from JMP Securities maintained a Buy rating on Haemonetics (HAE – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results